More than half of women diagnosed with breast cancer undergo breast-conserving surgery with a partial mastectomy. A new study from the Yale Cancer Center found that removing more tissue during this procedure could spare thousands of these patients from a second surgery.
More than half of women diagnosed with breast cancer undergo breast-conserving surgery with a partial mastectomy. A new study from the Yale Cancer Center found that removing more tissue during this procedure could spare thousands of these patients from a second surgery.
Somewhere between 20% and 40% of patients undergoing the procedure have cancer cells at the edge of what was removed, and the presence of these cells, or “positive margins,” often leads to a second surgery.
The researchers studied 235 patients with breast ranging from stage 0 to stage 3 with surgeons performing a partial mastectomy as usual. Patients were randomized in the operating room to either have additional tissue removed around the tumor site or not.
“Despite their best efforts, surgeons could not predict where the cancer was close to the edge,” the study’s lead author, Anees Chagpar, MD, MSc, MA, MPH, MBA, FRCS(C), FACS, associate professor of surgery (oncology) at Yale School of Medicine and director of The Breast Center at Smilow Cancer Hospital at Yale-New Haven, said in a statement. “Taking cavity shave margins cut the positive margin rate in half, without compromising cosmetic outcome or increasing complication rates.”
Patients in the study will be followed for 5 years to evaluate the impact of the technique on recurrence rates.
Data Back Neoadjuvant Combo vs Chemo Alone for Early-Stage NSCLC
April 24th 2024For patients with early-stage non–small cell lung cancer (NSCLC), combining neoadjuvant immune checkpoint inhibitors and platinum-based chemotherapy improves 2-year outcomes over chemotherapy alone, suggest findings of an extensive literature review and meta-analysis.
Read More
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
Polatuzumab Vedotin and R-CHP Appropriate for Untreated DLBCL
April 24th 2024Population pharmacokinetic and exposure-response analyses revealed a favorable benefit-risk profilane for the treatment combination of polatuzumab vedotin and rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHP).
Read More